We aimed to investigate salivary caffeine content, caffeine absorption and metabolism in Parkinson’s disease (PD) and verify whether salivary caffeine can be used as a biomarker of PD. We enrolled 98 PD patients and 92 healthy subjects. Caffeine and its major metabolite, paraxanthine, were measured in saliva samples collected before and 4 h after the oral intake of caffeine (100 mg). We measured caffeine absorption as the normalized increase in caffeine levels, and caffeine metabolism as the paraxanthine/caffeine ratio. The Movement Disorder Society Unified Parkinson's Disease Rating Scale part III, the Hoehn & Yahr, the presence of motor complications, and levodopa equivalent dose (LED) were assessed and correlated with caffeine levels, absorption, and metabolism. The effects of demographic and environmental features possibly influencing caffeine levels were also investigated. Caffeine levels were decreased in patients with moderate/advanced PD, while caffeine levels were normal in patients with early and de-novo PD, unrelated to caffeine intake. Caffeine absorption and metabolism were normal in PD. Decreased salivary caffeine levels in PD were associated with higher disease severity, longer duration, and the presence of motor complications, no significant association was found with LED. Salivary caffeine decrease correlates with PD progression.

Salivary caffeine in Parkinson’s disease / Leodori, G.; De Bartolo, M. I.; Belvisi, D.; Ciogli, A.; Fabbrini, A.; Costanzo, M.; Manetto, S.; Conte, A.; Villani, C.; Fabbrini, G.; Berardelli, A.. - In: SCIENTIFIC REPORTS. - ISSN 2045-2322. - 11:1(2021), p. 9823. [10.1038/s41598-021-89168-6]

Salivary caffeine in Parkinson’s disease

Leodori G.;De Bartolo M. I.;Belvisi D.;Ciogli A.;Fabbrini A.;Costanzo M.;Manetto S.;Conte A.;Villani C.;Fabbrini G.;Berardelli A.
2021

Abstract

We aimed to investigate salivary caffeine content, caffeine absorption and metabolism in Parkinson’s disease (PD) and verify whether salivary caffeine can be used as a biomarker of PD. We enrolled 98 PD patients and 92 healthy subjects. Caffeine and its major metabolite, paraxanthine, were measured in saliva samples collected before and 4 h after the oral intake of caffeine (100 mg). We measured caffeine absorption as the normalized increase in caffeine levels, and caffeine metabolism as the paraxanthine/caffeine ratio. The Movement Disorder Society Unified Parkinson's Disease Rating Scale part III, the Hoehn & Yahr, the presence of motor complications, and levodopa equivalent dose (LED) were assessed and correlated with caffeine levels, absorption, and metabolism. The effects of demographic and environmental features possibly influencing caffeine levels were also investigated. Caffeine levels were decreased in patients with moderate/advanced PD, while caffeine levels were normal in patients with early and de-novo PD, unrelated to caffeine intake. Caffeine absorption and metabolism were normal in PD. Decreased salivary caffeine levels in PD were associated with higher disease severity, longer duration, and the presence of motor complications, no significant association was found with LED. Salivary caffeine decrease correlates with PD progression.
parkinson's disease, caffeine
01 Pubblicazione su rivista::01a Articolo in rivista
Salivary caffeine in Parkinson’s disease / Leodori, G.; De Bartolo, M. I.; Belvisi, D.; Ciogli, A.; Fabbrini, A.; Costanzo, M.; Manetto, S.; Conte, A.; Villani, C.; Fabbrini, G.; Berardelli, A.. - In: SCIENTIFIC REPORTS. - ISSN 2045-2322. - 11:1(2021), p. 9823. [10.1038/s41598-021-89168-6]
File allegati a questo prodotto
File Dimensione Formato  
Leodori_Salivary caffeine inParkinson’s disease_2021.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 894.96 kB
Formato Adobe PDF
894.96 kB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1555359
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 3
social impact